Saniona publicerar sin delårsrapport för det första kvartalet 2022
May 25, 2022 02:00 ET
|
Saniona AB
Q1 2022 (Q1 2021) Intäkter uppgick till 6,6 MSEK (3,4 M)Rörelseresultat uppgick till -133,2 MSEK (-94,1 M)Periodens resultat uppgick till -133,4 MSEK (-83,4 M)Resultat per aktie uppgick till -2,14...
Saniona publishes its interim report for the first quarter of 2022
May 25, 2022 02:00 ET
|
Saniona AB
Q1 2022 (Q1 2021) Revenue was SEK 6.6 M (3.4 M)Operating loss was SEK -133.2 M (-94.1 M)Net loss was SEK -133.4 M (-83.4 M)Loss per share was SEK -2.14 (-1.34)Diluted loss per share was SEK -2.14...
Saniona uppdaterar om pågående granskning av tesofensin i Mexiko
May 20, 2022 03:45 ET
|
Saniona AB
PRESSMEDDELANDE 20 maj 2022 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att den mexikanska tillsynsmyndigheten...
Saniona provides update on ongoing review of tesofensine in Mexico
May 20, 2022 03:45 ET
|
Saniona AB
PRESS RELEASE May 20, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the Mexican regulatory authority Comisión Federal para la...
Saniona Changes Date of Annual Report for 2021
April 27, 2022 02:00 ET
|
Saniona AB
PRESS RELEASE April 27, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the Board of Directors of Saniona AB has resolved to...
Kallelse till årsstämma i Saniona AB
April 25, 2022 12:15 ET
|
Saniona AB
PRESSMEDDELANDE 25 april 2022 Aktieägarna i Saniona AB, org. nr 556962-5345, kallas härmed till årsstämma onsdagen den 25 maj 2022. Styrelsen har beslutat att årsstämman ska hållas enbart genom...
Notice of Saniona AB annual shareholders’ meeting
April 25, 2022 12:15 ET
|
Saniona AB
PRESS RELEASE April 25, 2022 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The...
Saniona tillkännager nytt strategiskt fokus på jonkanalsrelaterad FoU samt omstrukturering av styrelse och ledningsgrupp
April 25, 2022 10:25 ET
|
Saniona AB
PRESSMEDDELANDE 25 april 2022 Jørgen Drejer, medgrundare och styrelseledamot, kommer att föreslås till styrelseordförande; Thomas Feldthus, medgrundare, utses till VD; Anita Milland utses till...
Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team
April 25, 2022 10:25 ET
|
Saniona AB
PRESS RELEASE April 25, 2022 Jørgen Drejer, co-founder and board member, appointed interim Chairman of the Board of Directors; Thomas Feldthus, co-founder, appointed as CEO; Anita Milland...
Saniona Announces Strategic Program Prioritization and Restructuring to Streamline Operational Costs
March 29, 2022 10:00 ET
|
Saniona AB
PRESS RELEASE March 29, 2022 Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced a strategic program reprioritization and restructuring...